AstraZeneca edges higher after positive cancer drug study

Discussion in 'Market News' started by Lily, Jul 18, 2016.

  1. Lily

    Lily Forum Member

    Aug 29, 2015
    Likes Received:
    Experimental treatment Tagrisso meets targets in late stage trial

    AstraZeneca has moved higher after a successful trial of an experimental lung cancer drug.

    The pharmaceutical group said Tagrisso has met its main goal in a late stage study of its efficacy and safety as a second line treatment for certain types of lung cancer. Tagrisso, which AstraZeneca hopes will be one of the key drugs to rebuild sales as older products lose patent protection, has already received early approval from US and European regulators.

    Tagrisso and Lynparza (AstraZeneca’s PARP - poly ADP ribose polymerase -inhibitor) form part of AstraZeneca’s latest growth platform “New Oncology”, which was announced in February 2016 and alongside the five other growth platforms are important in bridging the earnings gap as the company hopes pipeline assets will deliver and contribute more meaningfully to growth.

    Continue reading...

Share This Page

free forex signals